Navigation Links
FDA: Potentially Harmful Stimulant Found in Slimming Beauty Capsules
Date:10/8/2010

SILVER SPRING, Md., Oct. 8 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today advised consumers who have Slimming Beauty Bitter Orange Slimming Capsules not to use the product. FDA warns that Slimming Beauty Bitter Orange Slimming Capsules contain the active pharmaceutical ingredient sibutramine, a prescription-only drug which is a stimulant. Sibutramine is not listed on the product label and could harm consumers, especially those with cardiovascular conditions.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

FDA lab tests reveal that the product contains excessive amounts of sibutramine that may be dangerous to people who have a history of cardiovascular disease, because it can lead to elevated blood pressure, stroke, and heart attack.

Consumers who are otherwise healthy and who take the amount of sibutramine found in Slimming Beauty capsules can experience anxiety, nausea, heart palpitations, a racing heart, insomnia, and elevated blood pressure. Sibutramine also may interact with other medications and can cause serious side effects.

Sibutramine is a powerful stimulant that should not be used without a prescription due to the safety risks associated with it.

Slimming Beauty is being sold over the Internet by Beautiful Health Inc., formerly LL Health and Beauty. Slimming Beauty sample packets also have been distributed by individuals at community events. The product and the sample packets are falsely labeled as "100% Herbal." The sample packet label is misleading because it indicates that it is a natural vitamin and calcium capsule for use in children as young as 2 years old.

The FDA has determined that Slimming Beauty sample packets were distributed at the 40th Annual Mexican Independence Day Parade in Chicago, on Sept. 12, 2010. The agency is aware of several reports of serious side effects from the use of this product including elevated blood pressure, headaches, vomiting, and insomnia.  

Consumers and health care professionals are encouraged to report adverse events related to the use of Slimming Beauty capsules to the FDA's MedWatch Safety Information and Adverse Event Reporting Program at www.fda.gov/MedWatch/report.htm or by phone at 800-FDA-1088 (800-332-1088).

Sample packets contain four capsules in a small, clear, plastic bag stapled to Slimming Beauty advertising material written in Spanish.

For more information:

FDA Drug Safety and Availability Web Page

http://www.fda.gov/Drugs/DrugSafety/default.htm

Media Inquiries: Elaine Gansz Bobo, 301-796-7567, elaine.bobo@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
2. Consumers at Risk: One in Six Wood Pallets in Los Angeles Discovered With Potentially Deadly Pathogens
3. New Montefiore Program Helps Patients Avoid Potentially Life-Threatening Medication Errors
4. NovaSom(R) Diagnostic System Can Assist in Raising Diagnosis Rate for Potentially Lethal Condition
5. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
6. New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. Intensive Chemotherapy May Be Harmful to Most Older Patients With Acute Myeloid Leukemia
9. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
10. DNA Test Predicts Harmful Effects of Cancer Drug
11. Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Indonesia , Jan. 17, 2017  With an annual growth ranging from 6% ... success. CPhI SEA (Jakarta International Expo, March 22-24, 2017) serves the industry ... What,s new at CPhI SEA 2017? Investment Forum ... Distributors, network Richer conference content Enhanced business matchmaking ... ...
(Date:1/18/2017)... , Jan. 18, 2017 Invetech, ... for cell and advanced therapies , has announced ... biopharmaceutical company developing "tumor starvation" treatments for acute ... needs. Under the agreement, Invetech will develop systems ... on Erytech,s proprietary ERYCAPS technology platform, which uses ...
(Date:1/18/2017)... MIAMI , January 18, 2017 ... announced the company plans to publish an online ... the Company,s preliminary sales forecast for 2017. Management ... Company,s trialing ninety-day record sales performance from its ... recently announced entry into the Cannabis sector ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
(Date:1/17/2017)... ... January 17, 2017 , ... SunView Software’s Service Smart Technology has been selected ... , Each year, Pink Elephant recognizes a new product or service developed ... specific business problem or opportunity. The award highlights original innovations that were released in ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
(Date:1/17/2017)... ... 2017 , ... Medic-CE , a Career Step company ... released four new continuing education courses as part of its Code3 CME Virtual ... classroom and meet the requirements of the National Continued Competency Program (NCCP), the ...
(Date:1/17/2017)... ... , ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum ... Design Challenge , the Cradle to Cradle Products Innovation Institute has announced. ... to run through early 2018. The challenges are presented by the Institute in partnership ...
Breaking Medicine News(10 mins):